Jamie Christensen
Venture Partner
Bio
James (Jamie) Christensen joins as a Venture Partner. Prior to joining OrbiMed, he was Executive Vice President of Research and Chief Scientific Officer at Mirati Therapeutics until its acquisition by Bristol Myers Squibb Company in 2024. Previously, Jamie was the head of Oncology Precision Medicine and a member of the executive leadership team in the Oncology Research Unit at Pfizer. Prior to Pfizer, he held positions at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team. Jamie began his industry experience at Warner Lambert/Parke-Davis in 1998. He has authored or co-authored 200+ peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, Cancer Discovery, the New England Journal of Medicine, and many others. In addition, he is a participant on the editorial boards for Cancer Research and Molecular Cancer Therapeutics and is a member of the board of directors at Boundless Bio.
Highlights:
- 25 years of experience in biopharmaceutical research focusing on oncology drug discovery, targeted therapies, and clinical development
- Key contributor to discovery, development, and eventual market authorization of multiple cancer therapies including
Sutent ® , Xalkori ®, Ibrance ®, and KRAZATI ® - Enjoys outdoor activities, including hiking, biking, and golf
